A Monocentric Randomized, Double-Blind, Placebo-Controlled Trial on the Effectiveness of Bioarginina® in Oral Administration for the Treatment of Asthenia in Patients without Associated Comorbidities

• DOI: 10.31546/ijfsnr.1007
• Publication Date: 2019-10-26T15:19:48Z
• Authors: Cuomo O; Simeone G; Minale M; Grieco F; Amella C; Alvisi V
• Keywords: 03 medical and health sciences; 0302 clinical medicine

In the last 6 decades a great debate about an idiopathic origin of moderate to severe asthenia was addressed by physicians.Asthenia is defined as symptom weakness related different conditions.It can be associated disabling symptoms such sore throat, cervical and axillary lymphadenopathy, myalgia, arthralgia, migraine, concentration, memory sleep disorders malaise after physical efforts.Arginine conditionally essential amino acid that involved in protein synthesis, detoxification ammonia, its conversion glucose well being catabolized produce energy; addition these physiological functions, arginine has shown have ergogenic potential.Arginine-based supplement may used on acute basis for delaying onset neuromuscular fatigue (i.e., PWCFT) improving ventilatory threshold.The present research conducted according experimental double-blind controlled design (vs.placebo), with aim evaluate clinical efficacy safety Bioarginina® (1.66g/20ml vials L-arginine) oral administration.The changes parameters relevant and/or mental fatigue, monitored evaluation treatment, showed clear difference patients treated compared those placebo, statistically better trend group than placebo group.The general conditions, especially at end observation period, improved significantly group.Overall, had marked improvement group, reduction almost 25% their intensity 30 days therapy over 70% treatment; contrast, symptomatology underwent impairment, assessable order 14% one month therapy.Overall results study strongly support effectiveness treatment highlight possibility application asthenia.